6.00
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Market Open
| Volume | 53 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
Best deals to access real time data! |
|
Small Cap Pro
Monthly Subscription
for only
|
|
Canna Trader Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Common Stock (QB) | QSAM | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
 |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 6.00 | 09:30:10 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.00 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 1 | 53 | - | 0.14 - 9.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:39:56 | 53 | $ 5.25 | USD |
Period:
Draw Mode:
Common Stock (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 10.12M | 1.69M | 302.05k | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 826.00 | $ - | - | - | - |
Common Stock (QB) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical QSAM Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.26 | 6.00 | 4.26 | 5.85 | 1,960 | 1.74 | 40.85% |
| 1 Month | 6.50 | 6.50 | 4.20 | 6.14 | 1,215 | -0.50 | -7.69% |
| 3 Months | 0.20 | 9.00 | 0.17 | 1.79 | 6,899 | 5.80 | 2,900.0% |
| 6 Months | 0.285 | 9.00 | 0.14 | 0.3635441 | 25,136 | 5.72 | 2,005.26% |
| 1 Year | 0.37 | 9.00 | 0.14 | 0.3521925 | 26,177 | 5.63 | 1,521.62% |
| 3 Years | 0.20 | 9.00 | 0.14 | 0.5263875 | 38,565 | 5.80 | 2,900.0% |
| 5 Years | 0.20 | 9.00 | 0.14 | 0.5263875 | 38,565 | 5.80 | 2,900.0% |
Common Stock (QB) Description
| QSAM Bioscience, Inc. is developing next generation nuclear medicines, including Samarium-153 DOTMP (CycloSam), for the treatment of bone cancer and related diseases. The FDA recently cleared QSAM's IND to commence Phase 1 clinical trials, and approved the company's application for Orphan Drug Designation for the indication of osteosarcoma, a devastating form of bone cancer that affects mainly children. QSAM is led by an experienced executive team and Board of Directors that have completed dozens of FDA approvals and multiple successful biotech exits. CycloSam has demonstrated preliminary safety and efficacy in animal studies and a single patient FDA-cleared human trial successfully performed in 2020. This multi-patented drug candidate utilizes an FDA approved radioisotope combined with a novel chelant that has demonstrated preliminary increased efficacy and decreased side effects in animal models and veterinary treatment of bone cancer in dogs. Further, CycloSam utilizes a streamlined, just-in-time manufacturing process that is already in place. Given these factors, management believes there is a strong pathway to commercialization for CycloSam. |